
Polybiomics: Seattle AI Profile — Product, Footprint & Verified Record

Verified: November 19, 2026 · Canonical URL: https://tygartmedia.com/polybiomics-seattle-wa-ai-profile/

Verified Record Summary: As of November 19, 2026, Polybiomics (Polybiomics Inc.) is an active, independent life-science AI startup with Washington ties spanning Plug and Play Seattle's Batch 2 cohort and a 2025 Washington Competes Grant listing in Kirkland. Its website lists 10 team members and a 4-member Scientific Advisory Board, while founding year and institutional venture funding remain undisclosed.



Field	Verified Record (As of Nov 19, 2026)
Company	Polybiomics (Polybiomics Inc.)
Official Website	https://www.polybiomics.com/
Washington HQ	Seattle, WA (Plug & Play Seattle Batch 2); also indexed in Kirkland, WA (WA Competes Grant) with earlier Berkeley, CA directory listings
Other WA Footprint	Kirkland, WA; UW CoMotion Labs (Seattle) and SNBL Global Gateway (Everett) via Plug & Play Seattle
Founded	Not publicly disclosed
Founders / Leadership	Mandana Veiseh, PhD (Founder, President & CSTO); Bahram Bahrami, PhD (Co-founder & CEO)
Stage	Accelerator / Grant-Backed
Announced Funding	Not publicly disclosed (2025 Washington Competes Grant recipient; program awards up to $25,000)
Team Size	10 listed on official website (2 executives + 8 team members; excludes 10 advisors)
Primary Ecosystem Ties	Plug and Play Seattle Batch 2 (Sept 2025); Life Science Washington Competes Grant (April 2025); Fred Hutch / UW research roots

What Polybiomics Builds

Polybiomics (Polybiomics Inc.) develops a modular, integrated live-cell analysis platform designed to observe dynamic cellular behavior without destroying samples. On polybiomics.com, the company organizes its architecture into three components: a proprietary **Bioinstrument and Consumable**, its **PolyData™ and Analytics** software layer, and an **AI engine** for actionable intelligence.

Conventional cell assays often rely on destructive endpoint measurements or capture only one parameter at a time. Polybiomics states that its proprietary polysensing consumable generates multi-parameter matrix data during imaging of a single live-cell sample, simultaneously and continuously tracking multiple phenotypes and biological functions without disturbing the cells or their 3D microenvironments. PolyData™ integrates those multimodal streams while the company's AI engine extracts predictive patterns intended to shorten discovery timelines, lower experimental costs, and improve reproducibility.

Washington Footprint and Leadership

Polybiomics has a multi-city West Coast footprint that requires careful reading across public directories. In September 2025, GeekWire listed 'Polybiomics, Seattle' as one of six local Seattle-area startups selected for **Plug and Play Seattle's Batch 2** accelerator, a 12-week program running through mid-December 2025 primarily at the University of Washington's CoMotion Labs with additional space at SNBL Global Gateway in Everett. Earlier in 2025 (April 8, 2025), Life Science Washington Institute and the Washington State Department of Commerce announced Polybiomics Inc.—indexed in **Kirkland, WA**—as a recipient of a Washington Competes Grant. Meanwhile, earlier Bay Area biotech and accelerator directories have listed Polybiomics in **Berkeley, California**, reflecting founder research ties at Lawrence Berkeley National Laboratory, and polybiomics.com itself omits a street address or city.

The company is led by Founder, President, and Chief Scientific and Technology Officer **Mandana Veiseh, PhD** and Co-founder and CEO **Bahram Bahrami, PhD**. Both founders share Pacific Northwest translational oncology research roots at Fred Hutchinson Cancer Research Center and the University of Washington, and Veiseh previously held research and technical roles at Lawrence Berkeley National Laboratory and Xerox-PARC. On polybiomics.com, Polybiomics lists eight additional team members (David Stumbo, PhD; Shahab S. Bahaei, PhD; Therese Choquette, PhD; Kayla Solomon, DMD; Bob Smith-McCollum, MBA; Ava Aslanpour, BE; Navya Mangipudi, BE; and Haro Hartounian, PhD), four Scientific Advisory Board members—including National Academy members Mina J. Bissell, PhD, Kurt Petersen, PhD, and Ron W. Davis, PhD, plus Rick Horwitz, PhD—and six business and legal advisors.

Products, Users, and Public Traction

Polybiomics positions its platform for four life-science buyer groups: academic researchers, pharmaceutical drug discovery teams, biomanufacturing operators, and clinical workflow teams. By consolidating multi-parameter monitoring onto a single non-destructive sample from early discovery through late-stage development, the company aims to cut reagent waste and improve experimental reproducibility.

Public commercial disclosures remain early-stage. Polybiomics has not published named pharmaceutical customers, instrument pricing, shipment counts, or peer-reviewed clinical deployments tied to the commercial product on polybiomics.com. Readers inspecting the site should also note that while its technical messaging aligns with its late-2025 Seattle accelerator profile, the website footer still displays a 2024 copyright notice (© 2024 POLYBIOMICS INC.) and routes inquiries through operations@polybiomics.com.

Funding, Stage, and Place in Washington's AI Landscape

No institutional venture capital round or cumulative equity raise has been publicly announced by Polybiomics through November 2026. Its verified Washington financial and program milestones are non-dilutive and accelerator-based: selection for the **Washington Competes Grant** (a state program administered by Life Science Washington Institute and the Washington Department of Commerce awarding up to $25,000 to early-stage Washington life-science companies) in April 2025, followed by selection for **Plug and Play Seattle Batch 2** in September 2025.

Within Washington's biotech-AI cluster, Polybiomics sits at the instrumentation-and-wet-lab boundary alongside Seattle AI drug-discovery peers like Clockwork Bio. Rather than relying solely on public molecular databases or pure in-silico models, Polybiomics pairs proprietary physical biosensing hardware and consumables with multimodal AI analysis—a capital-intensive, defensible approach closely aligned with Seattle's Fred Hutch, UW, and Eastside life-science research talent.

Verified Primary Sources & Official References

• Polybiomics Official Website: https://www.polybiomics.com/

• GeekWire — Plug and Play Seattle Batch 2 Cohort (Sept 19, 2025): https://www.geekwire.com/2025/plug-and-plays-second-seattle-area-accelerator-cohort-includes-six-local-startups/

• Life Science Washington: https://lifesciencewa.org/

• Plug and Play Seattle Hub Overview: https://www.plugandplaytechcenter.com/locations/seattle

Companion Markdown twin: https://tygartmedia.com/wp-content/uploads/2026/11/polybiomics-seattle-wa-ai-profile.md (also mirrored at https://tygartmedia.com/polybiomics-seattle-wa-ai-profile.md). Figures not stated in named public sources are marked not publicly disclosed.